Clinical Report: Gene Test May Refine Chemo Choices

Overview

A genomic test may help identify which patients with hormone receptor-positive, HER2-negative early breast cancer are most likely to benefit from anthracycline-containing chemotherapy.

Background

The identification of patients who will benefit from specific chemotherapy regimens is crucial in oncology, particularly for those with hormone receptor-positive, HER2-negative early breast cancer. Genomic assays like MammaPrint and BluePrint are emerging as tools to refine treatment decisions, potentially leading to more personalized care and reduced adverse effects from chemotherapy.

Data Highlights

Key Findings

• High-risk patients classified as High Risk 2 benefited from anthracycline-containing chemotherapy.
• Patients classified as High Risk 1 had similar outcomes regardless of whether anthracyclines were included.
• Standard clinical features did not distinguish patients who benefited from anthracyclines.
• The study utilized real-world data from 1,259 patients in the FLEX registry.
• Genomic profiling may help balance the benefits and risks of anthracyclines, including cardiac toxicity.

Clinical Implications

Further validation in randomized trials is necessary before widespread clinical adoption.

Conclusion

The study highlights the need for further research to validate these findings.

Related Resources & Content

1. William Audeh, JCO Precision Oncology, 2023 -- Gene Test May Refine Chemo Choices
2. the asco post — Genetic Testing May Reduce Chemotherapy Side Effects for Patients With GI Cancers
3. The New Gastroenterologist — Association of ctDNA Positivity with Chemotherapy Outcomes in Colorectal Cancer Patients
4. The ASCO Post — Standards of Care Confirmed in Latest Group of Colorectal Cancer Trials
5. the asco post — Molecular Assay Identifies Patients With Early NSCLC Likely to Benefit From Adjuvant Chemotherapy
6. Genetic Testing May Reduce Chemotherapy Side Effects for Patients With GI Cancers
7. Association of ctDNA Positivity with Chemotherapy Outcomes in Colorectal Cancer Patients
8. Standards of Care Confirmed in Latest Group of Colorectal Cancer Trials
9. Molecular Assay Identifies Patients With Early NSCLC Likely to Benefit From Adjuvant Chemotherapy
10. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update
11. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
12. https://academic.oup.com/jncics/article/9/5/pkaf079/8228535